Showing results (141-150 of 161) with videos related to
Sort By:
Pageof 17
Annals of Internal Medicine|August 15, 1996
Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120. A randomized, double-blind trial. NIAID AIDS Vaccine Evaluation GroupB S Graham, M C Keefer, M J McElrath, et al.Proceedings of the National Academy of Sciences of the United States of America|September 1, 1986
Prospect for prevention of human immunodeficiency virus infection: purified 120-kDa envelope glycoprotein induces neutralizing antibodyW G Robey, L O Arthur, T J Matthews, et al.Proceedings of the National Academy of Sciences of the United States of America|April 1, 1987
A conserved region at the COOH terminus of human immunodeficiency virus gp120 envelope protein contains an immunodominant epitopeT J Palker, T J Matthews, M E Clark, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 15, 1990
Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeysM K Hart, T J Palker, T J Matthews, et al.The Journal of Infectious Diseases|March 1, 1993
Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials NetworkB S Graham, T J Matthews, R B Belshe, et al.Biochemistry|September 20, 2000
Heptad-repeat regions of respiratory syncytial virus F1 protein form a six-membered coiled-coil complexM K Lawless-Delmedico, P Sista, R Sen, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 15, 1989
Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopesT J Palker, T J Matthews, A Langlois, et al.Clinical and Experimental Immunology|November 1, 1994
HIV-1 recombinant gp160 vaccine given in accelerated dose schedules. NIAID AIDS Vaccine Clinical Trials NetworkG J Gorse, D H Schwartz, B S Graham, et al.Nature|January 14, 1990
Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analoguesT D Meek, D M Lambert, G B Dreyer, et al.The Journal of Infectious Diseases|October 1, 1994
Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials NetworkB S Graham, G J Gorse, D H Schwartz, et al.Pageof 17